226 related articles for article (PubMed ID: 17691275)
21. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
[TBL] [Abstract][Full Text] [Related]
22. [Use of antihypertensive drugs in Spain (1995-2001)].
García del Pozo J; Ramos Sevillano E; de Abajo FJ; Mateos Campos R
Rev Esp Cardiol; 2004 Mar; 57(3):241-9. PubMed ID: 15056428
[TBL] [Abstract][Full Text] [Related]
23. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
Rathmann W; Haastert B; Icks A; Giani G
Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
[TBL] [Abstract][Full Text] [Related]
24. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003.
Chiang CW; Chiu HF; Chen CY; Wu HL; Yang CY
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):62-9. PubMed ID: 17924453
[TBL] [Abstract][Full Text] [Related]
25. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain.
Zara C; Torralba M; Sotoca JM; Prat A; Faixedas MT; Gilabert A
Ann Pharmacother; 2005 Jan; 39(1):177-82. PubMed ID: 15572601
[TBL] [Abstract][Full Text] [Related]
26. [Evolution of outpatient antibiotic use in Portugal mainland 2000-2009].
Ramalhinho I; Ribeirinho M; Vieira I; Cabrita J
Acta Med Port; 2012; 25(1):20-8. PubMed ID: 22883245
[TBL] [Abstract][Full Text] [Related]
27. [Osteoporosis treatment in Portugal: trends and geographical variation].
Rocha O; Lunet N; Costa L; Barros H
Acta Med Port; 2006; 19(5):373-80. PubMed ID: 17376323
[TBL] [Abstract][Full Text] [Related]
28. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
29. [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care].
Zambrowski JJ
Bull Cancer; 2008 May; 95(5):535-41. PubMed ID: 18541518
[TBL] [Abstract][Full Text] [Related]
30. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.
Martin BI; Turner JA; Mirza SK; Lee MJ; Comstock BA; Deyo RA
Spine (Phila Pa 1976); 2009 Sep; 34(19):2077-84. PubMed ID: 19675510
[TBL] [Abstract][Full Text] [Related]
31. [Increased use of lipid-lowering agents after implementation of clinical guidelines in general practice].
Bjerrum L; Larsen J; Kragstrup J
Ugeskr Laeger; 2003 Jan; 165(2):120-3. PubMed ID: 12553092
[TBL] [Abstract][Full Text] [Related]
32. Treatment of high-risk older persons with lipid-lowering drug therapy.
Aronow WS
Am J Ther; 2008; 15(2):102-7. PubMed ID: 18356628
[TBL] [Abstract][Full Text] [Related]
33. [Prescribing and dispensing generic drugs in the Mambéré-Kadéï health district of the Central African Republic].
Mouala C; Abeye J; Somse P; Maritoux J; Goumba A
Med Trop (Mars); 2008 Apr; 68(2):149-54. PubMed ID: 18630047
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998-2001.
Darbà J
Eur J Health Econ; 2003 Sep; 4(3):151-7. PubMed ID: 15609181
[TBL] [Abstract][Full Text] [Related]
35. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
36. Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in India.
Garg CC; Karan AK
Health Policy Plan; 2009 Mar; 24(2):116-28. PubMed ID: 19095685
[TBL] [Abstract][Full Text] [Related]
37. Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients.
Pratipanawatr T; Rawdaree P; Chetthakul T; Bunnag P; Ngarmukos C; Benjasuratwong Y; Leelawatana R; Kosachunhanun N; Plengvidhya N; Deerochanawong C; Suwanwalaikorn S; Krittiyawong S; Mongkolsomlit S; Komoltri C
J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S60-5. PubMed ID: 17715835
[TBL] [Abstract][Full Text] [Related]
38. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Kaló Z; Muszbek N; Bodrogi J; Bidló J
Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
[TBL] [Abstract][Full Text] [Related]
39. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of drug utilization from positive lists].
Perlík F; Kubica Z; Stika L
Cas Lek Cesk; 1999 Jan; 138(2):56-8. PubMed ID: 10376405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
